Gilead says it’s gaining clinical momentum with plans to grow its HIV franchise and nab an approval for an every-six-month pre-exposure prophylaxis (PrEP) approval.
Gilead’s third-quarter revenue total of $7.1 billion was driven by increased sales in HIV and oncology, the company said. In HIV products alone, Gilead pulled in…
Click here to view original post
